Business Context and Reporting Period
This Form 10-Q covers Advanced Polymer Systems, Inc. (not Heron Therapeutics, despite the metadata request) for the quarterly period ended September 30, 1995. The company operates in the polymer supply and consumer products sectors, including a marketing subsidiary (Premier, Inc.) that distributes sunscreen products for Johnson & Johnson. The business is noted as highly seasonal, with sales weighted toward the first two quarters of the year.
Key Financial Metrics
| Metric | 3 Months Ended Sep 30, 1995 | 9 Months Ended Sep 30, 1995 |
|---|---|---|
| Total Revenues | $3,056,546 | $12,938,966 |
| Gross Profit | $1,152,090 | $4,663,175 |
| Gross Margin | 37.7% | 36.0% |
| Operating Loss | ($2,193,522) | ($5,087,715) |
| Net Loss | ($1,998,829) | ($4,850,818) |
| Cash and Equivalents | $6,080,192 (Sep 30, 1995) | N/A |
| Working Capital | $7,753,376 | N/A |
| Total Debt (Current + Long-term) | $6,147,234 | N/A |
Material Changes vs. Prior Period
- Revenue: Three-month revenue decreased 10% to $3.06M, driven by lower licensing revenue ($20k vs $210k) and a slight dip in product sales. However, nine-month revenue was flat at $12.94M.
- Profitability: Gross margin improved significantly to 38% (3-month) and 36% (9-month) compared to 26% and 29% in the prior year, respectively. This was due to a favorable sales mix with higher-margin consumer products (Exact, Neet) and increased polymer supply shipments.
- Expenses: Operating expenses decreased 7% in the quarter and 12% for the nine months. Research & Development (R&D) spending dropped 44% in the quarter and 41% for the nine months as clinical studies for two New Drug Applications (NDAs) were completed.
- Net Loss: Net loss improved by 26% in the quarter ($1.99M vs $2.71M) and 33% for the nine months ($4.85M vs $7.29M).
- Liquidity: Cash and cash equivalents increased from $2.74M (Dec 31, 1994) to $6.08M (Sep 30, 1995), bolstered by $6.1M in new financing and $1.38M from a private placement.
Guidance, Outlook, and Risks
- Financing: The company secured $6.1M in new debt financing in Q3 1995: a $3M bank loan and a $3.1M secured loan. Additionally, $1.38M was raised via private placement.
- Debt Management: The company executed an "insubstance defeasance" of $2.5M in Industrial Revenue Bonds by placing U.S. government securities in an irrevocable trust, effectively removing this debt from the balance sheet.
- Product Outlook: Sales of Johnson & Johnson suncare products are expected to remain lower due to strategic inventory management. Growth is anticipated from the Exact acne product line and the newly acquired Neet depilatory products.
- Risks: The company faces a "take or pay" obligation to purchase minimum annual quantities of melanin; failure to do so in 1995 would trigger a mandatory $600,000 payment.
- Seasonality: Management warns that interim results are not indicative of full-year performance due to the seasonal nature of the sunscreen distribution business.
Investor Verification Checklist
- Verify the status of the two filed New Drug Applications (NDAs) for tretinoin and ProZone/Melanosponge.
- Confirm the terms and covenants of the new $6.1M debt facilities secured in Q3 1995.
- Assess the risk exposure related to the $600,000 "take or pay" melanin purchase obligation.
- Monitor the sales trajectory of the Exact and Neet product lines to ensure they offset the decline in J&J suncare revenue.
- Review the timeline for the remaining installments of the private placement agreement (noted as not being sold in the filing).